49
Participants
Start Date
October 31, 2008
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
EVP-6124 (0.1 mg/day)
EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
EVP-6124 (0.3 mg/day)
EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
EVP-6124 (1.0 mg/day)
EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
Comparator: Placebo
Matching placebo was administered as one capsule per day for 28 days.
Donepezil
Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
Rivastigmine
Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
MD Clinical, Hallandale
Pacific Research Network, Inc., San Diego
Comprehensive Clinical Research, Berlin
Global Medical Institutes, LLC, Princeton
Lead Sponsor
Collaborators (1)
Syneos Health
OTHER
FORUM Pharmaceuticals Inc
INDUSTRY